BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB), GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer

August 9, 2023 10:48:23

Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, and GEDi Cube Intl Ltd. have executed a binding, exclusive letter of intent (“LOI”). The LOI outlines the merge of a subsidiary with GEDi Cube, a cutting-edge health AI company. According to the announcement, the resulting company would focus on accelerating the diagnosis of cancer and other diseases, as well as enhancing treatment effectiveness, discovering new therapies and expanding access to life-saving technologies. According to the announcement, Renovaro Biosciences officials are confident that joining forces with GEDi Cube could “enhance the efficacy of upcoming trials and speed up the discovery of novel treatment approaches.” Renovaro is currently involved in studying pancreatic cancer and potential treatments; the company also plans to include other solid tumors with short life-expectancy in studies that are slated to start by mid-2024.

“I have been privileged to lead life sciences groups at Intel, Oracle and, most recently, NVIDIA,” said GEDi Cube International Ltd. CEO Craig Rhodes in the press release. “But GEDi Cube’s remarkably innovative technology developed over nearly a decade has already validated earlier diagnoses of lung cancer in humans at a leading university hospital and created the technology for 12 additional cancers, including pancreatic and breast cancer, which is very inspiring and exciting. We are rapidly expanding our technologies to include other cancers and diseases. I believe that uniting with Renovaro Biosciences’ potential solid tumor therapies is not merely synergistic. It could also create a multiplier effect to expedite diagnosis, improve treatment outcomes and discover, in silico, new therapies to improve many lives.”

To view the full press release, visit https://ibn.fm/hskUn

About Renovaro BioSciences Inc.

Renovaro BioSciences is an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company’s advanced cell, gene and immunotherapy techniques are designed to reinvigorate the body’s natural tumor-fighting mechanisms. For more information about the company, visit www.RenovaroBio.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork